---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026166"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:43:07.838271+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Genprex granted Singapore patent for Reqorsa with anti-PD-1 antibodies through 2037

## Summary
- Singapore Patent Office grants patent covering Reqorsa (quaratusugene ozeplasmid) in combo with anti-PD-1 antibodies until 2037.
- Patent expands on previously granted patents in U.S., Japan, Mexico, Russia, Australia, Chile, China, and Korea.
- Korean patent also claims Reqorsa with PD-L1 antibodies; Genprex plans similar filings in U.S., Brazil, Canada, China, Europe, Israel.
- Patent supports Acclaim-3 Phase 1/2 trial for ES-SCLC maintenance therapy combining Reqorsa with Tecentriq.

## SEC filing metadata
- accession: 0001437749-24-026166
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774924026166/0001437749-24-026166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774924026166/gnpx20240803_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026166
- JSON: https://secwatch.observer/filing/0001437749-24-026166.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026166.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.